Oncotarget

Research Papers:

Prognostic value of wait time in nasopharyngeal carcinoma treated with intensity modulated radiotherapy: a propensity matched analysis

Yu-Pei Chen, Yan-Ping Mao, Wen-Na Zhang, Lei Chen, Ling-Long Tang, Wen-Fei Li, Xu Liu, Guan-Qun Zhou, Rui Guo, Ying Sun, Tie-Bang Kang, Mu-Sheng Zeng and Jun Ma _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2016; 7:14973-14982. https://doi.org/10.18632/oncotarget.7789

Metrics: PDF 2209 views  |   HTML 2122 views  |   ?  


Abstract

Yu-Pei Chen1,*, Yan-Ping Mao1,*, Wen-Na Zhang1,*, Lei Chen1, Ling-Long Tang1, Wen-Fei Li1, Xu Liu1, Guan-Qun Zhou1, Rui Guo1, Ying Sun1, Tie-Bang Kang1, Mu-Sheng Zeng1, Jun Ma1

1Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, People’s Republic of China

*These authors contributed equally to this work

Correspondence to:

Jun Ma, e-mail: [email protected]

Keywords: nasopharyngeal carcinoma, wait time, intensity modulated radiotherapy, prognosis, propensity score matching

Received: October 08, 2015     Accepted: January 29, 2016     Published: February 29, 2016

ABSTRACT

The aim of this study was to determine the prognostic value of wait time from histological diagnosis to primary treatmen for nasopharyngeal carcinoma (NPC) treated with intensity-modulated radiotherapy (IMRT). Between October 2009 and February 2012, a total of 1672 NPC patients were retrospectively analyzed. A cutoff value of > 4 weeks was used to define prolonged wait time. Matched patients according to the wait time were identified using propensity score matching (PSM), which was also used to identify matched patients for subsequent stratified analyses. Differences in progression-free survival (PFS), overall survival (OS), distant metastasis-free survival (DMFS), and locoregional relapse-free survival (LRFS) were estimated using the Kaplan–Meier method and Cox proportional hazards models. In total, 407 pairs of NPC patients were selected by PSM. The 3-year PFS rate was significantly lower for patients with a prolonged wait time (> 4 weeks) than for those with an acceptable wait time (P = 0.035). Stratified analyses revealed that the negative effects of a prolonged wait time occurred primarily in patients with advanced NPC without neoadjuvant chemotherapy (NACT; PFS:P = 0.040; DMFS:P = 0.028). In multivariate analysis, a prolonged wait time was found to be an independent unfavorable prognostic factor for PFS and DMFS in advanced-staged patients without NACT. These results suggest that a prolonged time (> 4 weeks) between diagnosis and primary radical radiotherapy is a disadvantage for NPC patients, particularly those with advanced disease receiving no NACT. Thus, it is necessary to optimize resources for decreasing this wait time, although additional studies are warranted to further clarify our findings.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 7789